Why did profit double while revenue growth was more modest?

The Indore facility's EBITDA breakeven at just 30% utilization created operating leverage. As revenue scaled, a disproportionate amount flowed to the bottom line.

What does the 30% utilization breakeven imply for FY27 margins?

It sets a low bar for profitability. As utilization climbs above 30% in FY27, EBITDA should expand quickly, supporting the guided ~18% margin.

What are the new product agreements disclosed?

Gufic signed a CDMO agreement for GLP-1 products and an in-licensing deal for Canadian dermal fillers. The fillers complement its existing botulinum toxin portfolio.

What is changing in the company's international strategy?

Management is shifting the international business model toward holding its own marketing authorisations. This moves from a licensing model to owning IP in key markets.

Earnings · Pharmaceuticals · Small cap

Gufic posts best-ever quarter, profit doubles on Indore breakeven

Record ₹252 cr revenue and ₹20.5 cr net profit. The Indore plant's breakeven at 30% use is the operational driver behind the FY27 guidance.

GUFICBIO By Tipsheet Editorial 5 Jun 2026 · 6:14 PM IST Verify on BSE · NSE

Mkt cap₹3,710 cr

P/E57.77×

ROE11.59%

Debt / eq.0.52

Div yld0.03%

₹20.5 cr Q4 net profit, doubled year-on-year.

What's new

Q4 revenue hit a record ₹252 cr, with net profit doubling YoY to ₹20.5 cr.
The new Indore plant reached EBITDA breakeven at just 30% utilization.
Management guided for at least 15% revenue growth and ~18% EBITDA margin in FY27.

Why this matters

Breakeven at 30% utilization is a hard operational threshold. It means every percentage point of scale increase at Indore adds directly to EBITDA. The formal growth and margin guidance gives FY27 a concrete benchmark.

What we're watching

How quickly Indore utilization ramps above the 30% breakeven point through FY27.
Execution on the new GLP-1 CDMO agreement and Canadian filler in-licensing deal.
Debt trajectory, guided to stay near ₹400 cr despite the expansion push.

The full read

Gufic Biosciences' best quarter on record produced ₹252 crore in revenue and net profit of ₹20.5 crore, which doubled year-on-year. The operational driver is the new Indore facility reaching EBITDA breakeven at just 30% utilization. That low threshold explains management's confidence in guiding for at least 15% revenue growth and ~18% EBITDA margins in FY27. Every point of utilization above 30% at Indore should translate directly into higher margins. Beyond the facility, the company disclosed a CDMO pact for GLP-1 drugs and an in-licensing deal for Canadian dermal fillers, while shifting its international model toward owning marketing authorisations. Debt stays guided near ₹400 crore. The Indore breakeven number is the key. It turns the growth guidance from an aspiration into a function of a single plant's ramp-up.

Questions answered

Why did profit double while revenue growth was more modest?: The Indore facility's EBITDA breakeven at just 30% utilization created operating leverage. As revenue scaled, a disproportionate amount flowed to the bottom line.
What does the 30% utilization breakeven imply for FY27 margins?: It sets a low bar for profitability. As utilization climbs above 30% in FY27, EBITDA should expand quickly, supporting the guided ~18% margin.
What are the new product agreements disclosed?: Gufic signed a CDMO agreement for GLP-1 products and an in-licensing deal for Canadian dermal fillers. The fillers complement its existing botulinum toxin portfolio.
What is changing in the company's international strategy?: Management is shifting the international business model toward holding its own marketing authorisations. This moves from a licensing model to owning IP in key markets.

Mentioned: Indore facility · GLP-1 CDMO agreement · Canadian dermal fillers in-licensing

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.